Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ABI-4334 in Healthy Subjects
NCT05569941Phase 1Completed
- Sponsor
- Assembly Biosciences, Inc.
- Start
- Nov 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABI-4334 in Chronic Hepatitis B (CHB) (6 arms), sponsored by Assembly Biosciences, Inc. Primary endpoint: Adverse Events. Started Nov 2022; status: completed.
02
Drugs
ABI-4334
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05569941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05569941.